Stocktoria

SCYNEXIS INC SCYX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-05-02 · LEI

SCYNEXIS INC financials (annual)

Revenue
$257000 $257000 $257000 $121000 $0 $13.2M $5.1M $140.1M $3.7M $20.6M 2016201720182019202020212022202320242025
Net income
-$30.0M -$25.1M -$12.5M -$53.7M -$55.2M -$32.9M -$62.8M $67.0M -$21.3M -$8.6M 2016201720182019202020212022202320242025
Free cash flow
-$29.4M -$24.6M -$28.9M -$38.1M -$49.4M -$54.6M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$20.6M$3.7M$140.1M$5.1M$13.2M$0$121,000$257,000$257,000$257,000
R&D expense$22.3M$26.4M$30.9M$27.3M$23.8M$36.5M$38.4M$21.6M$18.3M$20.1M
SG&A expense$14.4M$14.5M$20.9M$63.0M$49.9M$14.6M$10.6M$8.7M$8.3M$8.0M
Operating income-$16.1M-$37.1M$72.7M-$85.8M-$60.8M-$51.1M-$48.9M-$30.0M-$26.3M-$27.8M
Interest expense$3.1M$5.2M$2.7M$1.2M$986,000$1.6M$1.5M$351,000
Income tax$0$151,000$138,000-$4.7M-$3.1M-$3.1M$0-$6.7M$0$0
Net income-$8.6M-$21.3M$67.0M-$62.8M-$32.9M-$55.2M-$53.7M-$12.5M-$25.1M-$30.0M
EPS (diluted)$-0.17$-0.44$1.39$-1.47$-1.25$-1.58
Operating cash flow-$5.3M-$24.0M$60.2M-$79.9M-$54.6M-$49.4M-$38.1M-$28.3M-$24.6M-$29.4M
Free cash flow-$54.6M-$49.4M-$38.1M-$28.9M-$24.6M-$29.4M
Cash & equivalents$21.3M$16.1M$34.0M$45.8M$104.5M$93.0M$41.9M$11.4M$11.5M$35.7M
Inventory$0$899,000$463,000$0
Total assets$59.0M$90.6M$128.4M$87.8M$119.8M$102.5M$57.2M$53.2M$45.9M$59.8M
Total liabilities$9.7M$35.6M$55.5M$84.6M$78.6M$79.8M$44.3M$21.9M$24.4M$25.0M
Shareholders' equity$49.4M$55.1M$73.0M$3.2M$41.3M$22.8M$12.9M$31.2M$21.4M$34.8M

Growth · year-over-year · Revenue CAGR 62.8%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+449.9%-97.3%+2652.7%-61.3%-100.0%-52.9%+0.0%+0.0%+0.0%
Net income growth-131.8%
EPS growth-131.7%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.